167 related articles for article (PubMed ID: 36727211)
1. Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
Scott JS; Stead D; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Cureton N; Davey PRJ; Fisher DI; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Hughes SJ; Hunt TA; Johnson T; Kavanagh SL; Klinowska TCM; Larner CJB; Lawson M; Lister AS; Longmire D; Marden S; McGuire TM; McMillan C; McMurray L; Morrow CJ; Nissink JWM; Moss TA; O'Donovan DH; Polanski R; Stokes S; Thakur K; Trueman D; Truman C; Tucker MJ; Wang H; Whalley N; Wu D; Wu Y; Yang B; Yang W
J Med Chem; 2023 Feb; 66(4):2918-2945. PubMed ID: 36727211
[TBL] [Abstract][Full Text] [Related]
2. Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
Scott JS; Moss TA; Balazs A; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Davey PRJ; Delpuech O; Fawell S; Fisher DI; Gagrica S; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Herlihy K; Hughes S; Hunt TA; Huynh H; Janbon SLM; Johnson T; Kavanagh S; Klinowska T; Lawson M; Lister AS; Marden S; McGinnity DF; Morrow CJ; Nissink JWM; O'Donovan DH; Peng B; Polanski R; Stead DS; Stokes S; Thakur K; Throner SR; Tucker MJ; Varnes J; Wang H; Wilson DM; Wu D; Wu Y; Yang B; Yang W
J Med Chem; 2020 Dec; 63(23):14530-14559. PubMed ID: 32910656
[TBL] [Abstract][Full Text] [Related]
3. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
4. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.
Lu Y; Liu C; Wang X; Liu L; Zhao Z; Liang Z; Liu Y; Wen Z; Du Q; Liu W
Eur J Med Chem; 2023 May; 253():115324. PubMed ID: 37019030
[TBL] [Abstract][Full Text] [Related]
7. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
Scott JS; Barlaam B
Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
[TBL] [Abstract][Full Text] [Related]
9. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
[TBL] [Abstract][Full Text] [Related]
10. Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD).
Lu J; Chan CC; Sun D; Hu G; He H; Li J; Dong J; Liu K; Shen L; Hu L; Gu Q; Chen S; Wang T; Gong T; Tang W; Li X; Zhu X; Zeng X; Zhu Y; Xia Y; Huang Y; Zhu Y; Liu Z; Ding CZ
Bioorg Med Chem Lett; 2022 Jun; 66():128734. PubMed ID: 35436589
[TBL] [Abstract][Full Text] [Related]
11. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
Hu B; Hu J
Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
[TBL] [Abstract][Full Text] [Related]
12. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
[TBL] [Abstract][Full Text] [Related]
13. SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
Zhou F; Yang G; Xue L; Liu Y; Guo Y; Zhu J; Yuan L; Gu P; Tang F; Shan J; Tang R
Breast Cancer Res; 2023 Aug; 25(1):96. PubMed ID: 37580832
[TBL] [Abstract][Full Text] [Related]
14. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
16. Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Burks HE; Abrams T; Kirby CA; Baird J; Fekete A; Hamann LG; Kim S; Lombardo F; Loo A; Lubicka D; Macchi K; McDonnell DP; Mishina Y; Norris JD; Nunez J; Saran C; Sun Y; Thomsen NM; Wang C; Wang J; Peukert S
J Med Chem; 2017 Apr; 60(7):2790-2818. PubMed ID: 28296398
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021-December 2023).
Scott JS; Klinowska TCM
Expert Opin Ther Pat; 2024 May; 34(5):333-350. PubMed ID: 38836316
[TBL] [Abstract][Full Text] [Related]
18. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
[TBL] [Abstract][Full Text] [Related]
19. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.
Liang J; Zbieg JR; Blake RA; Chang JH; Daly S; DiPasquale AG; Friedman LS; Gelzleichter T; Gill M; Giltnane JM; Goodacre S; Guan J; Hartman SJ; Ingalla ER; Kategaya L; Kiefer JR; Kleinheinz T; Labadie SS; Lai T; Li J; Liao J; Liu Z; Mody V; McLean N; Metcalfe C; Nannini MA; Oeh J; O'Rourke MG; Ortwine DF; Ran Y; Ray NC; Roussel F; Sambrone A; Sampath D; Schutt LK; Vinogradova M; Wai J; Wang T; Wertz IE; White JR; Yeap SK; Young A; Zhang B; Zheng X; Zhou W; Zhong Y; Wang X
J Med Chem; 2021 Aug; 64(16):11841-11856. PubMed ID: 34251202
[TBL] [Abstract][Full Text] [Related]
20. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
